Barrington lowered the firm's price target on Opko Health to $1.50 from $2.25 and keeps an Outperform rating on the shares. The company reported a better than expected Q4 report, but the way in which it achieved it is concerning, the analyst tells investors in a research note. The firm says "other revenue largely saved the quarter, but this level of performance is not sustainable."
